A recent study of HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab suggested that patients with ER-negative disease are more likely to achieve a pCR than those with ER-positive disease (19,20). Here, ERBB2 is linked to breast cancer.